SAB Biotherapeutics (NASDAQ:SABS) Receives Buy Rating from Chardan Capital

SAB Biotherapeutics (NASDAQ:SABS)‘s stock had its “buy” rating reissued by stock analysts at Chardan Capital in a report issued on Monday, Benzinga reports. They presently have a $25.00 target price on the stock.

Several other equities analysts also recently issued reports on SABS. Brookline Capital Management started coverage on SAB Biotherapeutics in a research report on Friday, June 7th. They set a “buy” rating and a $8.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of SAB Biotherapeutics in a research report on Monday, August 12th. Finally, Oppenheimer assumed coverage on shares of SAB Biotherapeutics in a research report on Wednesday, August 28th. They issued an “outperform” rating and a $12.00 target price for the company. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $12.75.

SAB Biotherapeutics Stock Down 1.1 %

SABS traded down $0.03 during trading on Monday, reaching $2.81. 766 shares of the company were exchanged, compared to its average volume of 14,489. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.24 and a quick ratio of 5.24. SAB Biotherapeutics has a 52 week low of $2.16 and a 52 week high of $10.50. The firm has a 50 day moving average of $2.77 and a 200 day moving average of $3.57.

SAB Biotherapeutics (NASDAQ:SABS) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.79) earnings per share for the quarter, beating the consensus estimate of ($1.13) by $0.34. The firm had revenue of $0.26 million for the quarter. SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.04%. As a group, equities research analysts expect that SAB Biotherapeutics will post -3.59 earnings per share for the current year.

Hedge Funds Weigh In On SAB Biotherapeutics

A number of hedge funds have recently modified their holdings of the stock. RTW Investments LP acquired a new stake in SAB Biotherapeutics during the 4th quarter worth about $6,310,000. BVF Inc. IL purchased a new stake in shares of SAB Biotherapeutics in the 4th quarter valued at approximately $6,310,000. Commodore Capital LP purchased a new position in SAB Biotherapeutics during the 4th quarter worth approximately $1,259,000. Finally, First PREMIER Bank acquired a new stake in SAB Biotherapeutics during the 2nd quarter valued at $60,000. 7.82% of the stock is currently owned by institutional investors and hedge funds.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.